Catalogue


Gene therapy of cancer [electronic resource] : translational approaches from preclinical studies to clinical implementation /
edited by Edmund C. Lattime, Stanton L. Gerson.
edition
3rd ed.
imprint
Amsterdam : Academic Press, c2014.
description
xv, 537 p. : ill.
ISBN
0123942950 (hbk.), 9780123942951 (hbk.)
format(s)
Book
More Details
imprint
Amsterdam : Academic Press, c2014.
isbn
0123942950 (hbk.)
9780123942951 (hbk.)
restrictions
Licensed for access to MSH users.
catalogue key
11166154
 
Includes bibliographical references and index.
A Look Inside
Reviews
Review Quotes
" ...represents the 'state-of-the-art', describing the progress made to date in its written chapters. ...this book is a worthy addition to the laboratories and libraries serving the students, fellows and experienced researchers devoted to translating cancer gene therapy applications from laboratory to the bedside."-Robert E. Sobol, GenStar Therapeutics, Sidney Kimmel Cancer Center
To find out how to look for other reviews, please see our guides to finding book reviews in the Sciences or Social Sciences and Humanities.
Summaries
Back Cover Copy
Gene Therapy as a treatment for cancer is at a critical point in its evolution. Exciting new developments in gene targeting and vector technology, coupled with results from the first generation of preclinical and clinical studies have led to the design and testing of new therapeutic approaches. The Second Edition of Gene Therapy of Cancer provides crucial updates on the basic and applied sciences of gene therapy. This volume offers a comprehensive assessment of the field including the areas of immunotherapy, suicide gene therapy, oncogene and suppressor gene targeting, drug resistance gene therapy, and the genetic modification of stem cells. Researchers at all levels of development, from basic laboratory investigators to clinical practitioners, will find this book to be instructive. Key Features * Provides in-depth description of targeted systems and treatment strategies * Explains the underlying cancer biology necessary for understanding proposed therapeutic approaches * Provides detailed illustrations of vector and therapeutic approaches ideal for classroom presentations and general reference * Divided into sections including: * Vectors for Gene Therapy of Cancer * Immune Targeted Gene Therapy * Oncogene-Targeted Gene Therapy * Manupulation of Drug Resistance Mechanisms by Gene Therapy * Anti-Angiogenesis and Pro-Apoptotic Gene Therapy * Prodrug Activation Strategies of Gene Therapy of Cancer
Bowker Data Service Summary
The third edition of 'Gene Therapy of Cancer' provides crucial updates on the basic and applied sciences of gene therapy. It offers a comprehensive assessment of the field including the areas of suicide gene therapy, oncogene and suppressor gene targeting, immunotherapy, drug resistance gene therapy, and the genetic modification of stem cells. Researchers at all levels of development, from basic laboratory investigators to clinical practitioners, will find this book to be instructive.
Main Description
Cancer gene therapy, like cancer therapy in general, is evolving rapidly, testing new concepts, targets and pathways, evoking new technologies, and passing new regulatory hurdles. Its essence, however, has not changed: the hope and challenges of returning altered genes to normal, using targeted gene expression to alter the function of both tumor and microenvironment, and in some cases normal cells, and delivering functionally important genes to specific cell types to increase sensitivity to killing or to protect normal cells from cancer therapies. In some instances, gene therapy for cancer forms a continuum from gene repair through the use of molecularly modified cells; the use of viral and non-viral vector based gene delivery to both tumor and tumor microenvironment; the use of viral and gene based vaccines; and development of new gene-based therapeutics. The unique mechanistically chosen vector platforms are at the heart of this technology because they allow for direct and selective cell death and transient to sustained delivery of vaccine molecules or molecules that affect the microenvironment, vasculature, or the immune response. Gene therapy as a treatment for cancer is at a critical point in its evolution. Exciting new developments in gene targeting and vector technology, coupled with results from the first generation of preclinical and clinical studies have led to the design and testing of new therapeutic approaches. The Third Edition of Gene Therapy of Cancer provides crucial updates on the basic and applied sciences of gene therapy. It offers a comprehensive assessment of the field including the areas of suicide gene therapy, oncogene and suppressor gene targeting, immunotherapy, drug resistance gene therapy, and the genetic modification of stem cells. Researchers at all levels of development, from basic laboratory investigators to clinical practitioners, will find this book to be instructive. Explains the underlying cancer biology necessary for understanding proposed therapeutic approaches Presents in-depth description of targeting systems and treatment strategiesCovers drug resistance gene therapy, gene therapy approaches, oncolytic viruses, as well as regulatory perspectives from both the NCI and FDA
Main Description
Cancer gene therapy, like cancer therapy in general, is evolving rapidly, testing new concepts, targets and pathways, evoking new technologies, and passing new regulatory hurdles. Its essence, however, has not changed: the hope and challenges of returning altered genes to normal, using targeted gene expression to alter the function of both tumor and microenvironment, and in some cases normal cells, and delivering functionally important genes to specific cell types to increase sensitivity to killing or to protect normal cells from cancer therapies. In some instances, gene therapy for cancer forms a continuum from gene repair through the use of molecularly modified cells; the use of viral and non-viral vector based gene delivery to both tumor and tumor microenvironment; the use of viral and gene based vaccines; and development of new gene-based therapeutics. The unique mechanistically chosen vector platforms are at the heart of this technology because they allow for direct and selective cell death and transient to sustained delivery of vaccine molecules or molecules that affect the microenvironment, vasculature, or the immune response. Gene therapy as a treatment for cancer is at a critical point in its evolution. Exciting new developments in gene targeting and vector technology, coupled with results from the first generation of preclinical and clinical studies have led to the design and testing of new therapeutic approaches. The Third Edition of Gene Therapy of Cancer provides crucial updates on the basic and applied sciences of gene therapy. It offers a comprehensive assessment of the field including the areas of suicide gene therapy, oncogene and suppressor gene targeting, immunotherapy, drug resistance gene therapy, and the genetic modification of stem cells. Researchers at all levels of development, from basic laboratory investigators to clinical practitioners, will find this book to be instructive. Explains the underlying cancer biology necessary for understanding proposed therapeutic approaches Presents in-depth description of targeting systems and treatment strategies Covers drug resistance gene therapy, gene therapy approaches, oncolytic viruses, as well as regulatory perspectives from both the NCI and FDA
Main Description
The goal of the 3e of "Gene Therapy of Cancer "is to provide a comprehensive review of state-of-the-art advances in the field of gene-based therapeutics from discovery to model building through to clinical intervention. The overall breadth of research covered in this expanded 3e is far greater than in previous editions because of recent advances in non-viral vector development, including the use of inhibitory RNA and the expanded efforts in oncolytic viruses. Many of these areas were in their infancy in the last edition. New focus will be placed on studies in the area of oncolytic viruses and genetic fusion vaccines, taking advantage of recent clinical advancements. Further emphasis will be placed on the defined field of drug resistance gene therapy as well as on the use of imaging factors in gene therapy approaches. Important new chapters will also include insider perspectives on regulatory review and approval from the National Cancer Institute and the Food and Drug Administration. Explains the underlying cancer biology necessary for understanding proposed therapeutic approaches Presents in-depth description of targeting systems and treatment strategiesCovers drug resistance gene therapy, gene therapy approaches, oncolytic viruses, as well as regulatory perspectives from both the NCI and FDA
Main Description
The goal of the 3e of Gene Therapy of Cancer is to provide a comprehensive review of state-of-the-art advances in the field of gene-based therapeutics from discovery to model building through to clinical intervention. The overall breadth of research covered in this expanded 3e is far greater than in previous editions because of recent advances in non-viral vector development, including the use of inhibitory RNA and the expanded efforts in oncolytic viruses. Many of these areas were in their infancy in the last edition. New focus will be placed on studies in the area of oncolytic viruses and genetic fusion vaccines, taking advantage of recent clinical advancements. Further emphasis will be placed on the defined field of drug resistance gene therapy as well as on the use of imaging factors in gene therapy approaches. Important new chapters will also include insider perspectives on regulatory review and approval from the National Cancer Institute and the Food and Drug Administration. Explains the underlying cancer biology necessary for understanding proposed therapeutic approaches Presents in-depth description of targeting systems and treatment strategies Covers drug resistance gene therapy, gene therapy approaches, oncolytic viruses, as well as regulatory perspectives from both the NCI and FDA
Main Description
The third edition of "Gene Therapy of Cancer" provides crucial updates on the basic and applied sciences of gene therapy. It offers a comprehensive assessment of the field, including the areas of suicide gene therapy, oncogene and suppressor gene targeting, immunotherapy, drug resistance gene therapy, and the genetic modification of stem cells. Researchers at all levels of development, from basic laboratory investigators to clinical practitioners, will benefit from this book. Cancer gene therapy is evolving rapidly, testing new concepts, targets and pathways, evoking new technologies, and passing new regulatory hurdles. With the ultimate goal of returning altered genes to normal, gene therapy for cancer can, in some instances, form a continuum from gene repair through: The use of molecularly modified cellsThe use of viral and non-viral vector-based gene delivery to both tumor and tumor microenvironmentThe use of viral and gene based vaccinesDevelopment of new gene-based therapeutics This volume considers these unique mechanistically chosen vector platforms in depth, because they allow for direct and selective cell death and transient to sustained delivery of vaccine molecules or molecules that affect the microenvironment, vasculature, or the immune response. Gene therapy as a treatment for cancer is at a critical point in its evolution. Exciting new developments in gene targeting and vector technology, coupled with results from the first generation of preclinical and clinical studies have led to the design and testing of these promising new therapeutic approaches. Explains the underlying cancer biology necessary for understanding proposed therapeutic approaches Presents in-depth description of targeting systems and treatment strategiesCovers drug resistance gene therapy, gene therapy approaches, oncolytic viruses, as well as regulatory perspectives from both the NCI and FDA
Main Description
The third edition of Gene Therapy of Cancer provides crucial updates on the basic and applied sciences of gene therapy. It offers a comprehensive assessment of the field, including the areas of suicide gene therapy, oncogene and suppressor gene targeting, immunotherapy, drug resistance gene therapy, and the genetic modification of stem cells. Researchers at all levels of development, from basic laboratory investigators to clinical practitioners, will benefit from this book. Cancer gene therapy is evolving rapidly, testing new concepts, targets and pathways, evoking new technologies, and passing new regulatory hurdles. With the ultimate goal of returning altered genes to normal, gene therapy for cancer can, in some instances, form a continuum from gene repair through: The use of molecularly modified cells The use of viral and non-viral vector-based gene delivery to both tumor and tumor microenvironment The use of viral and gene based vaccines Development of new gene-based therapeutics This volume considers these unique mechanistically chosen vector platforms in depth, because they allow for direct and selective cell death and transient to sustained delivery of vaccine molecules or molecules that affect the microenvironment, vasculature, or the immune response. Gene therapy as a treatment for cancer is at a critical point in its evolution. Exciting new developments in gene targeting and vector technology, coupled with results from the first generation of preclinical and clinical studies have led to the design and testing of these promising new therapeutic approaches. Explains the underlying cancer biology necessary for understanding proposed therapeutic approaches Presents in-depth description of targeting systems and treatment strategies Covers drug resistance gene therapy, gene therapy approaches, oncolytic viruses, as well as regulatory perspectives from both the NCI and FDA

This information is provided by a service that aggregates data from review sources and other sources that are often consulted by libraries, and readers. The University does not edit this information and merely includes it as a convenience for users. It does not warrant that reviews are accurate. As with any review users should approach reviews critically and where deemed necessary should consult multiple review sources. Any concerns or questions about particular reviews should be directed to the reviewer and/or publisher.

  link to old catalogue

Report a problem